Literature DB >> 11786681

Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration.

F Kanda1, S Okuda, T Matsushita, K Takatani, K I Kimura, K Chihara.   

Abstract

Glucocorticoids have been widely used in the treatment of autoimmune and other diseases. Chronic steroid use, however, could cause proximal muscle weakness and atrophy, termed steroid myopathy. The onset of steroid myopathy is usually insidious and there are no specific laboratory findings except for elevated urinary creatine excretion. Muscle biopsy reveals non-specific type II fiber atrophy. There are many reports showing preventive effects of either growth hormone (GH) or insulin-like growth factor (IGF)-I on steroid myopathy. The pathogenesis of steroid myopathy is not fully understood. Recently, glutamine synthetase has been reported to play a key role in steroid myopathy. GH as well as IGF-I decreased the steroid-induced glutamine synthetase activity in skeletal muscle. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11786681     DOI: 10.1159/000048130

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  16 in total

Review 1.  Physiological and methodological considerations for the use of neuromuscular electrical stimulation.

Authors:  Nicola A Maffiuletti
Journal:  Eur J Appl Physiol       Date:  2010-05-15       Impact factor: 3.078

Review 2.  [Lipid lowering drug and other toxic myopathies].

Authors:  B G H Schoser; D Pongratz
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

3.  The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies.

Authors:  M A Minetto; A Rainoldi; J F Jabre
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

4.  A case of an infant with flail tricuspid valve due to spontaneous papillary muscle rupture: was neonatal lupus the culprit?

Authors:  G A Fleming; F G Scholl; A Kavanaugh-McHugh; M R Liske
Journal:  Pediatr Cardiol       Date:  2007-09-20       Impact factor: 1.655

5.  Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force.

Authors:  R T Hinkle; E Donnelly; D B Cody; M B Bauer; R J Sheldon; R J Isfort
Journal:  J Muscle Res Cell Motil       Date:  2005-02-09       Impact factor: 2.698

6.  Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis.

Authors:  Kazutaka Masamoto; Bungo Otsuki; Shunsuke Fujibayashi; Koichiro Shima; Hiromu Ito; Moritoshi Furu; Motomu Hashimoto; Masao Tanaka; Stephen Lyman; Hiroyuki Yoshitomi; Shimei Tanida; Tsuneyo Mimori; Shuichi Matsuda
Journal:  Eur Spine J       Date:  2017-11-28       Impact factor: 3.134

Review 7.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

8.  Subacute steroid-induced paraparesis: surgical treatment of a devastating "invisible" side effect.

Authors:  M Javad Mirzayan; M Javad Mirzayan; Thomas Goessling; Tobias Huefner; Joachim K Krauss
Journal:  Eur Spine J       Date:  2012-02-28       Impact factor: 3.134

Review 9.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

Review 10.  Diagnostic work-up in steroid myopathy.

Authors:  Marco Alessandro Minetto; Valentina D'Angelo; Emanuela Arvat; Santosh Kesari
Journal:  Endocrine       Date:  2017-11-15       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.